An interventional study of Protein CC16 in Acute Bronchiolitis, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 1 Day to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-06.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Treatment
Acute bronchiolitis is a common viral infection in infants mainly due to RSV and rhinovirus.
Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of epithelial aggression. Its rate increase during RSV bronchiolitis in infants less than 7 months. It could be an early predictive biomarker of the severity of acute bronchiolitis, and secondarily for the development of asthma.
Two other markers of airway aggression seem to increase during acute bronchiolitis: serum SP-D protein and serum soluble receptor sRAGE.
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system established at the time of the admission in Paediatric Emergency Unit. Secondary end-points: correlation with urinary CC16; correlation with risk factors for bronchial epithelial aggression, viruses, immediate morbidity and mortality. Study of serum SP-D and sRAGE levels.
360 studies on the registry are indexed under Bronchiolitis; 43 are open to participants now.
This study's planned enrollment of 200 is above the median of 80 across 249 interventional studies indexed under Bronchiolitis.
Browse Bronchiolitis studies →University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
Drug: Protein CC16
Serum CC16 rate
Time frame: at day 1
Urinary CC16 rate
Time frame: at day 1
SP-D rates
Time frame: at day 1
sRAGE rates
Time frame: at day 1
This study is status unknown, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand